A consent decree has been filed against Ranier’s Compounding Laboratory in Jeannette prohibiting the Westmoreland County company from manufacturing or distributing medications labeled as sterile due to alleged unsanitary conditions at the facility.
The injunction, entered in U.S. District Court in Pittsburgh by the U.S. Department of Justice on behalf of the Food and Drug Administration, covers human and animal drugs.
The complaint by the FDA filed with the consent decree alleges Ranier’s produced and sold adulterated drugs, including injectables for conditions such as erectile dysfunction and ophthalmic drugs used as anesthetics, antibiotics and cataract therapies, among others.
Under the agreement, Ranier’s cannot resume sterile compounding operations until completing corrective actions and receiving approval from the FDA.
A phone call seeking comment from Ranier’s owner, Francis H. Ranier, was not returned.
In July, the FDA issued an alert, warning Ranier’s customers not to use products labeled as sterile because of concerns over cleanliness.
The agency sent a warning letter to Ranier’s in March 2017 after inspectors found its sterile products were “prepared, packed or held under insanitary conditions.”
During a follow-up inspection in May 2018, the agency again found “poor sterile production practices,” such as staff not changing gloves before working in a sterile processing area and not properly disinfecting pieces of equipment before placing them in the aseptic processing area.
“We continue to see concerning activity when it comes to some compounded drugs … which can raise significant risks to patients,” the FDA said in a news release late Wednesday.
“Despite our warning, Ranier’s and its owner placed patients at risk by compounding purportedly sterile drug products under insanitary conditions.”
Consumers with questions can contact the FDA at 1-888-463-6332.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.
This story was originally published with images that are no longer available.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.